Outcomes and phenotypic expression of rare variants in hypertrophic cardiomyopathy genes amongst UK Biobank participants

Antonio de Marvao, Kathryn A. McGurk, Sean L. Zheng, Marjola Thanaj, Wenjia Bai, Jinming Duan, Carlo Biffi, Francesco Mazzarotto, Ben Statton, Timothy J. W. Dawes, Nicoló Savioli, Brian P. Halliday, Xiao Hua Xu, Rachel Buchan, A. John Baksi, Marina Quinlan, Paweł Tokarczuk, Upasana Tayal, Catherine Francis, Nicola Whiffin, Pantazis Theotokis, Xiaolei Zhang, Mikyung Jang, Alaine Berry, Antonios Pantazis, Paul J.r. Barton, Daniel Rueckert, Sanjay Prasad, Roddy Walsh, Carolyn Y. Ho, Stuart A. Cook, James S. Ware, Declan P. O’ReganmedRxiv 2021 · DOI

Abstract

Hypertrophic cardiomyopathy (HCM) is traditionally characterized by unexplained left ventricular hypertrophy and is primarily caused by rare variants in sarcomere-encoding genes. While well-studied in clinical cohorts, the significance of these variants in the general population remains poorly understood. This study utilizes the UK Biobank to compare outcomes and cardiovascular phenotypes in over 200,000 participants stratified by sarcomere-encoding variant status. The findings reveal that while pathogenic variants have low aggregate penetrance for overt hypertrophy, they are associated with a significantly increased risk of adverse cardiovascular outcomes, particularly heart failure and arrhythmia.

Introduction

Hypertrophic Cardiomyopathy (HCM) is the most common genetic heart disease. Historically, our understanding of the condition has been shaped by "clinical cohorts"—individuals from families with a known history of the disease or patients already presenting with symptoms. This creates a significant selection bias, potentially overestimating the danger of certain genetic variants while overlooking their effects in the broader population.

As whole-exome sequencing (WES) becomes more accessible, clinicians are increasingly identifying HCM-associated variants in asymptomatic individuals without a family history. This study addresses a critical clinical question: Does a pathogenic HCM mutation carry the same risk in a "healthy" individual as it does in a patient from a high-risk family?

Methods

Researchers conducted an observational study of 218,813 adults from the UK Biobank, integrating three distinct analytical domains:

  1. Genomics: Participants were categorized based on WES data into three groups: Pathogenic/Likely Pathogenic (SARC-P/LP), Indeterminate (SARC-IND), and Genotype Negative (SARC-NEG) using ClinVar, gnomAD, and the CardioClassifier tool.
  2. Machine Learning Imaging: To achieve high-throughput, high-accuracy measurements, the team employed a deep-learning neural network to segment Cardiac Magnetic Resonance (CMR) images. This allowed for sub-pixel measurement of myocardial wall thickness (WT) across nearly 40,000 subjects.
  3. Survival Analysis: Cox proportional hazards models were used to determine the hazard ratios (HR) for death and major adverse cardiac events (MACE), adjusting for age and sex.

Key Insights

The "Silent" Risk and Low Penetrance

The most significant finding is the decoupling of genetic risk from physical expression (phenotype). In clinical families, the penetrance of HCM (the proportion of carriers who show physical symptoms) is high. However, in this general population study, only 16% of individuals with a pathogenic variant (SARC-P/LP) met the clinical threshold for hypertrophy (wall thickness ≥13mm).

Despite this low structural penetrance, these individuals remained at high risk. Carriers of SARC-P/LP variants faced a 4.40x higher risk of heart failure and a 1.55x higher risk of arrhythmia compared to controls. This suggests that the genetic mutation confers a "silent" risk that exists even when the heart appears structurally normal on a standard scan.

The Significance of Indeterminate Variants

A major challenge in genetic counseling is the "variant of uncertain significance." This study found that rare sarcomere-encoding variants that did not meet the strict P/LP criteria (SARC-IND) had a negligible effect on wall thickness and no associated increase in cardiovascular risk (HR 1.00). This provides evidence that many rare variants in these genes may not require the same level of clinical concern as known pathogenic mutations.

Phenotypic Expression

While most carriers did not meet the 13mm threshold for HCM, they did exhibit subtle structural changes. On average, SARC-P/LP carriers had thicker heart walls (10.9mm vs. 9.4mm) and showed signs of concentric remodeling (increased mass-to-volume ratio). This indicates a sub-clinical cardiomyopathic phenotype that precedes overt disease.

Clinical Implications and Limitations

These findings suggest a need to re-evaluate how we monitor genetic carriers. The current reliance on wall thickness as the primary marker for HCM may miss individuals at high risk for heart failure and arrhythmia.

However, the study has limitations. The UK Biobank is subject to a "healthy volunteer" bias, and the cohort is 85% Caucasian, which may limit the generalizability of the results to more diverse populations. Furthermore, while the study establishes a clear link between these variants and adverse outcomes, the exact mechanism—whether driven by sub-clinical fibrosis or microvascular dysfunction—requires further investigation.

Conclusion

In the general population, pathogenic sarcomeric variants are found in approximately 1 in 423 individuals. While these variants rarely lead to overt hypertrophy, they significantly increase the lifetime risk of heart failure and death. This study highlights the importance of genetic data in risk stratification, even in the absence of traditional clinical symptoms.

Summary updated

Abstract

Abstract Background Hypertrophic cardiomyopathy (HCM) is caused by rare variants in sarcomere-encoding genes, but little is known about the clinical significance of these variants in the general population. Methods We compared outcomes and cardiovascular phenotypes in UK Biobank participants with whole exome sequencing stratified by sarcomere-encoding variant status. Results The prevalence of rare variants (allele frequency <0.00004) in HCM-associated sarcomere-encoding genes in 200,584 participants was 2.9% (n=5,727; 1 in 35), of which 0.24% (n=474, 1 in 423) were pathogenic or likely pathogenic variants (SARC-P/LP). SARC-P/LP variants were associated with increased risk of death or major adverse cardiac events compared to controls (HR 1.68, 95% CI 1.37-2.06, p<0.001), mainly due to heart failure (HR 4.40, 95% CI 3.22-6.02, p<0.001) and arrhythmia (HR 1.55, 95% CI 1.18-2.03, p=0.002). In 21,322 participants with cardiac magnetic resonance imaging, SARC-P/LP were associated with increased left ventricular maximum wall thickness (10.9±2.7 vs 9.4±1.6 mm, p<0.001) and concentric remodelling (mass/volume ratio: 0.63±0.12 vs 0.58±0.09 g/mL, p<0.001), but hypertrophy (≥13mm) was only present in 16% (n=7/43, 95% CI 7-31%). Other rare sarcomere-encoding variants had a weak effect on wall thickness (9.5±1.7 vs 9.4±1.6 mm, p=0.002) with no combined excess cardiovascular risk (HR 1.00 95% CI 0.92-1.08, p=0.9). Conclusions In the general population, SARC-P/LP variants have low aggregate penetrance for overt HCM but are associated with an increased risk of adverse cardiovascular outcomes and a sub-clinical cardiomyopathic phenotype. In contrast, rare sarcomeric variants that do not meet criteria to be classified as P/LP appear to have minimal clinical impact.
BibTeX
@misc{marvao2021outcomes,
  author = {Antonio de Marvao and Kathryn A. McGurk and Sean L. Zheng and Marjola Thanaj and Wenjia Bai and Jinming Duan and Carlo Biffi and Francesco Mazzarotto and Ben Statton and Timothy J. W. Dawes and Nicoló Savioli and Brian P. Halliday and Xiao Hua Xu and Rachel Buchan and A. John Baksi and Marina Quinlan and Paweł Tokarczuk and Upasana Tayal and Catherine Francis and Nicola Whiffin and Pantazis Theotokis and Xiaolei Zhang and Mikyung Jang and Alaine Berry and Antonios Pantazis and Paul J.R. Barton and Daniel Rueckert and Sanjay Prasad and Roddy Walsh and Carolyn Y. Ho and Stuart A. Cook and James S. Ware and Declan P. O’Regan},
  title = {{Outcomes and phenotypic expression of rare variants in hypertrophic cardiomyopathy genes amongst UK Biobank participants}},
  year = {2021},
  doi = {10.1101/2021.01.21.21249470},
  howpublished = {medRxiv},
}
Figure